SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
April 19, 2005
HALOZYME THERAPEUTICS, INC.
|(State or other jurisdiction||(Commission||(IRS Employer|
|of incorporation)||File Number)||Identification No.)|
|11588 Sorrento Valley Road, Suite 17, San Diego, California
|(Address of principal executive offices)
Registrants telephone number, including area code: (858) 794-8889
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|Item 8.01 Other Events.|
|Item 9.01 Financial Statements and Exhibits.|
Item 8.01 Other Events.
On April 19, 2005, Halozyme Therapeutics, Inc. (the Company) announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CumulaseÔ for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The press release announcing the Companys 510(k) clearance is filed as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
|Press Release dated April 19, 2005.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc.
|April 19, 2005||By:||/s/ Jonathan E. Lim, MD|
|Jonathan E. Lim, MD|
|President and CEO|